CPH 0.00% 0.9¢ creso pharma limited

Ann: Halucenex Phase II Clinical Trial Update, page-46

  1. 3,250 Posts.
    lightbulb Created with Sketch. 1046
    so they dosed 2 per week over 10 weeks for a total 20 participants, and expect completion 2Q2023. Remaining results should be then weekly until late June.

    keen to see what the whole cohort reveals.
 
watchlist Created with Sketch. Add CPH (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.